Pharma Companies Face Important Decision: Choosing Between Salesforce and Veeva
A big change is coming for pharmaceutical and biotech companies. Two major customer relationship management (CRM) providers, Salesforce and Veeva, […]
Pharmacist Explains: The Rise of Immunotherapy Drugs
Hello there! I’m a pharmacist, and I’m here to explain some exciting news in the world of medicine. You might
Hope for Huntington’s Disease: New Gene Therapy Shows Promise
Last month, there was exciting news for people with Huntington’s disease. A new gene therapy called AMT-130, made by uniQure,
Pharmaceutical News
Bristol Myers Squibb Buys Orbital Therapeutics for $1.5 Billion to Boost Cell Therapy Options
Bristol Myers Squibb (BMS) has bought Orbital Therapeutics, a US biotech company, for $1.5 billion. This deal is mainly about
New Hope for Type 1 Diabetes: Vertex Pharmaceuticals’ Breakthrough Treatment
Vertex Pharmaceuticals, known for its groundbreaking CRISPR-based therapy for sickle cell disease, is now focusing on Type 1 diabetes. Their
Nobel Prize Honors Breakthroughs in Immunology, Sparking Hope for New Treatments
Immunology is a powerful tool in the world of medicine, helping to create new treatments for various conditions, from cancer
Pharmaceutical News
FDA Takes Action Against Novo Nordisk’s Indiana Manufacturing Site
A pharmaceutical manufacturing site in Indiana, now owned by Novo Nordisk after their purchase of Catalent in 2024, has been
New Hope for Follicular Lymphoma Patients with Fast Track Designation for EO2463
Enterome, a biopharmaceutical company, has been given a special status called ‘fast track designation’ by the US Food and Drug
Big Boost for Health Research: £157 Million to Improve Care Across England
The National Institute for Health and Care Research (NIHR) has big plans to improve healthcare. They’re investing £157 million over
MindMed’s LSD-Based Treatment Shows Promise for Anxiety Disorders
The field of psychedelics-based drug development has been promising for mental health treatments, but it hasn’t yet delivered significant breakthroughs.